Hill-Rom’s division Welch Allyn has launched a PC-based resting electrocardiograph (ECG), Connex Cardio ECG, to improve decision-making and patient outcomes in the US.
The new device features a combination of Veritas interpretation algorithm, wireless Mortara technology and flexible Welch Allyn EMR connectivity.
Intended to simplify clinical workflows, the resting ECG will allow identification, management and tracking of conditions such as heart disease and stroke.
Hill-Rom Front Line Care business president Alton Shade said: “Better patient outcomes begin with better data, which is why we incorporated the Veritas resting ECG algorithm in the Connex Cardio solution.
“Healthcare providers can be confident they are interpreting the right data to support the best clinical decisions.”
Veritas is said to comply with American College of Cardiology (ACC), American Heart Association (AHA) and Heart Rhythm Society (HRS) recommendations for ECG filtering and acquisition in both adults and paediatrics.
The US Food and Drug Administration (FDA) uses the algorithm to monitor patients in Phase I and II drug clinical trials and upon receiving the submission of new drug applications to its ECG Warehouse for a cardiac safety review.
With Connex Cardio, an ECG can be captured and saved in just two clicks through the EMR, while the device’s WAM wireless acquisition facilitates easy capture without cable tether between the patient and the PC.
Connex Cardio ECG is part of Welch Allyn cardiopulmonary range of diagnostic cardiology solutions and is set to be available globally from next year.